Literature DB >> 15561304

The use of whole genome amplification in the study of human disease.

Simon Hughes1, Nona Arneson, Susan Done, Jeremy Squire.   

Abstract

The availability of large amounts of genomic DNA is of critical importance for many of the molecular biology assays used in the analysis of human disease. However, since the amount of patient tissue available is often limited and as particular foci of interest may consist of only a few hundred cells, the yield of DNA is often insufficient for extensive analysis. To address this problem, several whole genome amplification (WGA) methodologies have been developed. Initial WGA approaches were based on the polymerase chain reaction (PCR). However, recent reports have described the use of non-PCR-based linear amplification protocols for WGA. Using these methods, it is possible to generate microgram quantities of DNA starting with as little as 1mg of genomic DNA. This review will provide an overview of WGA approaches and summarize some of the uses for amplified DNA in various high-throughput genetic applications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15561304     DOI: 10.1016/j.pbiomolbio.2004.01.007

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  24 in total

1.  Limited tissue fixation times and whole genomic amplification do not impact array CGH profiles.

Authors:  A A Ghazani; N C R Arneson; K Warren; S J Done
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

2.  Phylogenetic fate mapping: theoretical and experimental studies applied to the development of mouse fibroblasts.

Authors:  Stephen J Salipante; James M Thompson; Marshall S Horwitz
Journal:  Genetics       Date:  2008-02-03       Impact factor: 4.562

3.  A procedure for highly specific, sensitive, and unbiased whole-genome amplification.

Authors:  Xinghua Pan; Alexander Eckehart Urban; Dean Palejev; Vincent Schulz; Fabian Grubert; Yiping Hu; Michael Snyder; Sherman M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-01       Impact factor: 11.205

4.  A new whole genome amplification method for studying clonal evolution patterns in malignant colorectal polyps.

Authors:  Daniela Hirsch; Jordi Camps; Sudhir Varma; Ralf Kemmerling; Mark Stapleton; Thomas Ried; Timo Gaiser
Journal:  Genes Chromosomes Cancer       Date:  2012-02-15       Impact factor: 5.006

Review 5.  Preimplantation genetic diagnosis: state of the art 2011.

Authors:  Joyce C Harper; Sioban B Sengupta
Journal:  Hum Genet       Date:  2011-07-12       Impact factor: 4.132

Review 6.  Preimplantation genetic diagnosis: an update on current technologies and ethical considerations.

Authors:  Kou Sueoka
Journal:  Reprod Med Biol       Date:  2015-11-14

7.  Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content.

Authors:  Coren A Milbury; Clark C Chen; Harvey Mamon; Pingfang Liu; Sandro Santagata; G Mike Makrigiorgos
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

8.  Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues.

Authors:  Ronald van Eijk; Marjo van Puijenbroek; Amiet R Chhatta; Nisha Gupta; Rolf H A M Vossen; Esther H Lips; Anne-Marie Cleton-Jansen; Hans Morreau; Tom van Wezel
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

9.  Assessing the efficiency and significance of Methylated DNA Immunoprecipitation (MeDIP) assays in using in vitro methylated genomic DNA.

Authors:  Jinsong Jia; Aleksandra Pekowska; Sebastien Jaeger; Touati Benoukraf; Pierre Ferrier; Salvatore Spicuglia
Journal:  BMC Res Notes       Date:  2010-09-16

10.  DNA degradation test predicts success in whole-genome amplification from diverse clinical samples.

Authors:  Fengfei Wang; Lilin Wang; Christine Briggs; Ewa Sicinska; Sandra M Gaston; Harvey Mamon; Matthew H Kulke; Raffaella Zamponi; Massimo Loda; Elizabeth Maher; Shuji Ogino; Charles S Fuchs; Jin Li; Carlos Hader; G Mike Makrigiorgos
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.